Research analysts at HC Wainwright initiated coverage on shares of Polaryx Therapeutics (NASDAQ:PLYX – Get Free Report) in a note issued to investors on Thursday,Benzinga reports. The brokerage set a “buy” rating and a $7.00 price target on the stock. HC Wainwright’s price target would suggest a potential upside of 174.51% from the stock’s previous close.
Separately, Weiss Ratings upgraded Polaryx Therapeutics from a “sell (e-)” rating to a “sell (e)” rating in a report on Wednesday, July 1st. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Polaryx Therapeutics has an average rating of “Hold” and a consensus price target of $8.50.
Get Our Latest Report on Polaryx Therapeutics
Polaryx Therapeutics Trading Up 0.8%
Polaryx Therapeutics (NASDAQ:PLYX – Get Free Report) last released its quarterly earnings results on Monday, March 23rd. The company reported ($0.03) EPS for the quarter.
Insider Activity
In other news, CEO Alex Keun Mo Yang purchased 88,453 shares of the stock in a transaction dated Wednesday, May 27th. The stock was acquired at an average cost of $4.07 per share, for a total transaction of $360,003.71. Following the completion of the acquisition, the chief executive officer directly owned 24,233,249 shares in the company, valued at $98,629,323.43. This represents a 0.37% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.
Polaryx Therapeutics Company Profile
We are a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (“LSDs”). Our therapeutic philosophy is centered on delivering safe, effective, and patient-friendly treatments that address the underlying pathophysiology of these catastrophic diseases and their significant unmet need. Our multi-modal approach integrates small molecule therapies, including a combination therapy, and a gene therapy, positioning us to potentially address both the genetic and downstream pathological features of LSDs.
Featured Articles
- Five stocks we like better than Polaryx Therapeutics
- Sony Is Going All-Digital—But Investors Should Watch This Instead
- Scotiabank Sees a New Growth Story for Cloudflare
- A Market Panic Just Discounted the AI Highway’s Tollbooth
- Why Exxon Could Be the Market’s Next Big Comeback Stock
Receive News & Ratings for Polaryx Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Polaryx Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
